PURPOSE: To assess feasibility, complications, local tumor recurrences, overall survival (OS), and estimates of cost effectiveness for multisite cryoablation (MCA) of oligometastatic non-small-cell lung cancer (NSCLC). MATERIALS AND METHODS: A total of 49 computed tomography- and/or ultrasound-guided percutaneous MCA procedures were performed on 60 tumors in 31 patients (19 women and 12 men) with oligometastatic NSCLC. Average patient age was 65 years. Tumor location was grouped according to common metastatic sites. Median OS was determined by Kaplan-Meier method and defined life-years gained (LYGs). Estimates of MCA costs per LYG were compared with established values for systemic therapies. RESULTS: Total numbers of tumors and cryoablation procedures for each anatomic site were as follows: lung, 20 and 18; liver, nine and seven; superficial, 12 and 11; adrenal, seven and seven; paraaortic/isolated, two and two; and bone, 10 and seven. A mean of 1.6 procedures per patient were performed, with a median clinical follow-up of 11 months. Major complication and local recurrence rates were 8% (four of 49) and 8% (five of 60), respectively. Median OS for MCA was 1.33 years, with an estimated 1-year survival rate of approximately 53%. MCA appeared cost-effective even when added to the cost of best supportive care or systemic regimens, with an adjunctive cost-effectiveness ratio of $49,008-$87,074. CONCLUSIONS: MCA was associated with very low morbidity and local tumor recurrence rates for all anatomic sites, and possibly increased OS. Even as an adjunct to systemic therapies, MCA appeared cost-effective for palliation of oligometastatic NSCLC.
PURPOSE: To assess feasibility, complications, local tumor recurrences, overall survival (OS), and estimates of cost effectiveness for multisite cryoablation (MCA) of oligometastatic non-small-cell lung cancer (NSCLC). MATERIALS AND METHODS: A total of 49 computed tomography- and/or ultrasound-guided percutaneous MCA procedures were performed on 60 tumors in 31 patients (19 women and 12 men) with oligometastatic NSCLC. Average patient age was 65 years. Tumor location was grouped according to common metastatic sites. Median OS was determined by Kaplan-Meier method and defined life-years gained (LYGs). Estimates of MCA costs per LYG were compared with established values for systemic therapies. RESULTS: Total numbers of tumors and cryoablation procedures for each anatomic site were as follows: lung, 20 and 18; liver, nine and seven; superficial, 12 and 11; adrenal, seven and seven; paraaortic/isolated, two and two; and bone, 10 and seven. A mean of 1.6 procedures per patient were performed, with a median clinical follow-up of 11 months. Major complication and local recurrence rates were 8% (four of 49) and 8% (five of 60), respectively. Median OS for MCA was 1.33 years, with an estimated 1-year survival rate of approximately 53%. MCA appeared cost-effective even when added to the cost of best supportive care or systemic regimens, with an adjunctive cost-effectiveness ratio of $49,008-$87,074. CONCLUSIONS:MCA was associated with very low morbidity and local tumor recurrence rates for all anatomic sites, and possibly increased OS. Even as an adjunct to systemic therapies, MCA appeared cost-effective for palliation of oligometastatic NSCLC.
Authors: L E Quint; S Tummala; L J Brisson; I R Francis; A S Krupnick; E A Kazerooni; M D Iannettoni; R I Whyte; M B Orringer Journal: Ann Thorac Surg Date: 1996-07 Impact factor: 4.330
Authors: Ronald S Arellano; Vincent L Flanders; Susanna I Lee; Peter R Mueller; Debra A Gervais Journal: AJR Am J Roentgenol Date: 2010-06 Impact factor: 3.959
Authors: S Novello; A Kielhorn; G Stynes; G Selvaggi; F De Marinis; A Maestri; P Foggi; D Tilden; M Tonato; L Crinò; M Rinaldi; A M Migliorino; G V Scagliotti Journal: Lung Cancer Date: 2005-02-12 Impact factor: 5.705
Authors: Geoffrey A Porter; Scott B Cantor; Garrett L Walsh; Valerie W Rusch; Dennis H Leung; Alma Y DeJesus; Raphael E Pollock; Murray F Brennan; Peter W T Pisters Journal: J Thorac Cardiovasc Surg Date: 2004-05 Impact factor: 5.209
Authors: Tristan D Yan; Julie King; Adrian Sjarif; Derek Glenn; Karin Steinke; Ahmed Al-Kindy; David L Morris Journal: Ann Surg Oncol Date: 2007-02-07 Impact factor: 5.344
Authors: Cesare Gridelli; Andrea Ardizzoni; Fortunato Ciardiello; Nasser Hanna; John V Heymach; Francesco Perrone; Rafael Rosell; Frances A Shepherd; Nick Thatcher; Johan Vansteenkiste; Luigi De Petris; Massimo Di Maio; Filippo De Marinis Journal: J Thorac Oncol Date: 2008-04 Impact factor: 15.609
Authors: Roberto Luigi Cazzato; Julien Garnon; Nitin Ramamurthy; Guillaume Koch; Georgia Tsoumakidou; Jean Caudrelier; Francesco Arrigoni; Luigi Zugaro; Antonio Barile; Carlo Masciocchi; Afshin Gangi Journal: Med Oncol Date: 2016-11-11 Impact factor: 3.064
Authors: Errol Colak; Servet Tatlı; Paul B Shyn; Kemal Tuncalı; Stuart G Silverman Journal: Diagn Interv Radiol Date: 2014 Jul-Aug Impact factor: 2.630
Authors: Jesse J Veenstra; Heather M Gibson; Peter J Littrup; Joyce D Reyes; Michael L Cher; Akira Takashima; Wei-Zen Wei Journal: Cancer Res Date: 2014-08-04 Impact factor: 12.701
Authors: Peter J Littrup; Hyun J Bang; Brandt P Currier; Dylan J Goodrich; Hussein D Aoun; Lance K Heilbrun; Barbara A Adam Journal: J Vasc Interv Radiol Date: 2013-09-20 Impact factor: 3.464
Authors: J Louis Hinshaw; Meghan G Lubner; Timothy J Ziemlewicz; Fred T Lee; Christopher L Brace Journal: Radiographics Date: 2014 Sep-Oct Impact factor: 5.333